| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | NEUTRAL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 4.12▲ | 4.13▼ | 4.14▼ | 4.24▼ | 4.21▼ |
| MA10 | 4.12▲ | 4.15▼ | 4.17▼ | 4.21▼ | 4.13▲ |
| MA20 | 4.13▼ | 4.19▼ | 4.25▼ | 4.19▼ | 4.05▲ |
| MA50 | 4.15▼ | 4.27▼ | 4.24▼ | 4.15▼ | 4.66▼ |
| MA100 | 4.18▼ | 4.25▼ | 4.18▼ | 4.28▼ | 4.13▼ |
| MA200 | 4.25▼ | 4.18▼ | 4.18▼ | 4.86▼ | 3.01▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.002▲ | -0.005▼ | -0.019▼ | 0.000▼ | 0.037▲ |
| RSI | 46.759▼ | 37.678▼ | 37.880▼ | 47.169▼ | 46.837▼ |
| STOCH | 54.233 | 14.167▼ | 10.201▼ | 56.327 | 62.095 |
| WILL %R | -44.444 | -82.143▼ | -91.525▼ | -72.619 | -41.573 |
| CCI | 59.725 | -131.765▼ | -97.282 | -26.555 | 78.434 |
|
Wednesday, May 13, 2026 01:24 PM
Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026Affirms existing clinical data is sufficient for ...
|
|
Wednesday, May 13, 2026 01:17 PM
Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union, ...
|
|
Tuesday, May 12, 2026 07:07 AM
Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 13/05/26 | 4.24 | 4.24 | 4.10 | 4.13 | 2,135,815 |
| 12/05/26 | 4.31 | 4.40 | 4.16 | 4.16 | 1,396,578 |
| 11/05/26 | 4.31 | 4.435 | 4.25 | 4.34 | 1,382,289 |
| 08/05/26 | 4.25 | 4.36 | 4.245 | 4.32 | 1,881,167 |
| 07/05/26 | 4.23 | 4.30 | 4.155 | 4.23 | 1,298,773 |
| 06/05/26 | 4.17 | 4.3299 | 4.135 | 4.23 | 1,628,322 |
| 05/05/26 | 4.22 | 4.29 | 4.13 | 4.18 | 973,175 |
| 04/05/26 | 4.18 | 4.285 | 4.18 | 4.22 | 1,085,569 |
| 01/05/26 | 4.13 | 4.225 | 4.105 | 4.20 | 965,166 |
| 30/04/26 | 4.07 | 4.165 | 4.06 | 4.10 | 903,680 |
|
|
||||
|
|
||||
|
|